Children and adolescents’ immunization in 2025
How to use the schedule
소아 사춘기 아이들2025년 예방 접종 스케듈
Vaccines and Other Immunizing Agents in the Child and Adolescent Immunization Schedul
To make vaccinatione recommendations, healthcare providers should:
- Determine recommended vaccine by age (Table 1 – By Age)
- Determine recommended interval for catch-up vaccination (Table 2 – Catch-up)
- Assess need for additional recommended vaccines by medical condition or other indication (Table 3 – By Medical Indication)
- Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)
- Review contraindications and precautions for vaccine types (Appendix)
- Review new or updated ACIP guidance (Addendum)
Birth to 15 Months
| Range of recommended ages for all children | Range of recommended agesfor catch-up vaccination | Range of recommended ages for certain high-risk groups or populations | Recommended vaccination can begin in this age group | Recommended vaccination based on shared clinical decision-making | No Guidance/Not Applicable |
These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2).
| Vaccine and other immunizing agents | Birth | 1 mo | 2 mos | 4 mos | 6 mos | 9 mos | 12 mos | 15 mos | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
Respiratory syncytial virus  (RSV-mAb [Nirsevimab]) |
1 dose depending on maternal RSV vaccination status, See Notes | 1 dose (8 through 19 months), See Notes | |||||||||
| Hepatitis B (HepB) |
1st dose | ←2nd dose→ | ←3rd dose→ | ||||||||
| Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) |
1st dose | 2nd dose | See Notes | ||||||||
| Diphtheria, tetanus, & acellular pertussis (DTaP: <7 yrs) |
1st dose | 2nd dose | 3rd dose | ←4th dose→ | |||||||
| Haemophilus influenzae type b (Hib) |
1st dose | 2nd dose | See Notes | ←3rd or 4th dose, See Notes→ |
|||||||
| Pneumococcal conjugate (PCV15, PCV20) |
1st dose | 2nd dose | 3rd dose | ←4th dose→ | |||||||
| Inactivated poliovirus (IPV) |
1st dose | 2nd dose | ←3rd dose→ | ||||||||
| COVID-19 (1vCOV-mRNA, 1vCOV-aPS) |
1 or more doses of 2024–2025 vaccine (See Notes) |
||||||||||
| Influenza (IIV3, ccIIV3) |
1 or 2 doses annually | ||||||||||
| Influenza (LAIV3) |
|||||||||||
| Measles, mumps, rubella (MMR) |
See Notes | ←1st dose→ | |||||||||
| Varicella (VAR) |
←1st dose→ | ||||||||||
| Hepatitis A (HepA) |
(See Notes) | ←2-dose series, See Notes→ | |||||||||
| Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) |
|||||||||||
| Human papillomavirus (HPV) |
|||||||||||
| Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years) |
See Notes | ||||||||||
| Meningococcal B (MenB-4C, MenB-FHbp) |
|||||||||||
| Respiratory syncytial virus vaccine (RSV [Abrysvo]) |
|||||||||||
| Dengue (DEN4CYD: 9-16 yrs) |
|||||||||||
| Mpox |
|||||||||||
18 Months to 18 Years
| Vaccine and other immunizing agents | 18mos | 19-23mos | 2-3yrs | 4-6yrs | 7-10yrs | 11-12yrs | 13-15 yrs | 16yrs | 17-18yrs | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Respiratory syncytial virus (RSV-mAb [Nirsevimab]) |
1 dose (8 through 19 months), See Notes | |||||||||||||||||||||||||
| Hepatitis B (HepB) |
←3rd dose→ | |||||||||||||||||||||||||
| Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) |
||||||||||||||||||||||||||
| Diphtheria, tetanus, & acellular pertussis(DTaP: <7 yrs) |
←4th dose→ | 5th dose | ||||||||||||||||||||||||
| Haemophilus influenzae type b (Hib) |
||||||||||||||||||||||||||
| Pneumococcal conjugate (PCV15, PCV20) |
||||||||||||||||||||||||||
| Inactivated poliovirus (IPV) |
←3rd dose→ | 4th dose | SeeNotes | |||||||||||||||||||||||
| COVID-19 (1vCOV-mRNA, 1vCOV-aPS) |
1 or more doses of 2024–2025 vaccine(See Notes) | |||||||||||||||||||||||||
| Influenza (IIV3, ccIIV3) |
1 or 2 doses annually | 1 dose annually | ||||||||||||||||||||||||
|
Influenza (LAIV3) |
1 or 2 doses annually |
|
1 dose annually | |||||||||||||||||||||||
| Measles, mumps, rubella (MMR) |
2nd dose | |||||||||||||||||||||||||
| Varicella (VAR) |
2nd dose | |||||||||||||||||||||||||
| Hepatitis A (HepA) |
← 2-dose series, See Notes→ | |||||||||||||||||||||||||
| Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) |
1 dose | |||||||||||||||||||||||||
| Human papillomavirus (HPV) |
See Notes | |||||||||||||||||||||||||
| Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years) |
See Notes | 1st dose | 2nd dose | |||||||||||||||||||||||
| Meningococcal B (MenB-4C, MenB-FHbp) |
See Notes | |||||||||||||||||||||||||
| Respiratory syncytial virus vaccine (RSV [Abrysvo]) |
Seasonal administration during pregnancy, See Notes | |||||||||||||||||||||||||
| Dengue (DEN4CYD: 9–16 yrs) |
Seropositive in endemic dengue areas (See Notes) | |||||||||||||||||||||||||
| Mpox |
||||||||||||||||||||||||||
To make vaccination recommendations, healthcare providers should:
- Determine recommended vaccine by age (Table 1 – By Age)
- Determine recommended interval for catch-up vaccination (Table 2 – Catch-up)
- Assess need for additional recommended vaccines by medical condition or other indication (Table 3 – By Medical Indication)
- Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)
- Review contraindications and precautions for vaccine types (Appendix)
- Review new or updated ACIP guidance (Addendum)
Source. Pediatrics 2025